Lexeo Therapeutics Inc (LXEO)

$9.04 +0.05 (0.56%)
Market Cap 659.80M
Revenue (ttm) 0.00
Net Income (ttm) -98.33M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 484,800
Avg Vol 1,295,256
Day's Range N/A - N/A
Shares Out 72.99M
Stochastic %K 70%
Beta 1.75
Analysts Strong Sell
Price Target $19.11

Company Profile

Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 547 9879
Address:
345 Park Avenue South, 6th Floor, New York, United States
RunnerSignals
RunnerSignals Nov. 11 at 9:33 PM
Analysts Spotlight for our pro subscribers $LXEO $ADMA $AMD $ORCL $NVTS are catching analyst attention with strong upside potential https://stocksrunner.com/news/2025-11-11-analysts-spotlight-stocks-with-strong-upside-potential-today
0 · Reply
RunnerSignals
RunnerSignals Nov. 11 at 9:24 PM
Comeback Kings 👑$ACHR $JOBY $TDW $NTLA $LXEO They dipped they flipped they conquered! turned lows into highs classic trader magic
1 · Reply
StockConsultant
StockConsultant Nov. 11 at 3:48 AM
$LXEO Lexeo Therapeutics stock watch, attempting to rally off the 8.31 double support area
1 · Reply
shortkiller7
shortkiller7 Nov. 7 at 3:26 PM
$LXEO is end. Come on $BCAB
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 12:18 AM
Chardan Capital has adjusted their stance on Lexeo Therapeutics ( $LXEO ), setting the rating to Buy with a target price of 17.
1 · Reply
d_risk
d_risk Nov. 5 at 4:20 PM
$LXEO - Lexeo Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors LXEO’s latest 10-Q adds new risks on clinical trial enrollment, orphan/rare disease designations, manufacturing and supply chain issues, reimbursement, privacy/cybersecurity, and expanded regulatory and IP compliance challenges, while removing some prior details on international operations, tax, and cybersecurity breach risks. #Biotechnology #RegulatoryCompliance #ManufacturingRisks #OrphanDiseases #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/LXEO/10-Q/2025-11-05
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 11:11 AM
HC Wainwright & Co. updates rating for Lexeo Therapeutics ( $LXEO ) to Buy, target set at 15 → 13.
0 · Reply
DonCorleone77
DonCorleone77 Oct. 17 at 10:56 AM
$LXEO Lexeo Therapeutics 15.625M share Spot Secondary priced at $8.00
0 · Reply
DonCorleone77
DonCorleone77 Oct. 16 at 8:34 PM
$LXEO Lexeo announces common stock and warrants offering, no amount given
0 · Reply
JarvisFlow
JarvisFlow Oct. 15 at 2:26 PM
Guggenheim updates rating for Lexeo Therapeutics ( $LXEO ) to Buy, target set at 30.
0 · Reply
Latest News on LXEO
Lexeo Therapeutics: Behind The Rebound

Nov 6, 2025, 4:59 PM EST - 10 days ago

Lexeo Therapeutics: Behind The Rebound

Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights

Nov 5, 2025, 7:36 AM EST - 11 days ago

Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights

Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters' Option to Purchase Additional Shares in the Public Offering

Oct 20, 2025, 4:05 PM EDT - 27 days ago

Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters' Option to Purchase Additional Shares in the Public Offering

Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement

Oct 16, 2025, 11:29 PM EDT - 4 weeks ago

Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement

Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

Oct 16, 2025, 4:32 PM EDT - 4 weeks ago

Lexeo Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

Lexeo: Maintaining Buy Rating Based On FDA Accelerated Approval Feedback

Oct 7, 2025, 3:22 PM EDT - 5 weeks ago

Lexeo: Maintaining Buy Rating Based On FDA Accelerated Approval Feedback

Lexeo Therapeutics, Inc. - Special Call

Oct 7, 2025, 12:45 PM EDT - 5 weeks ago

Lexeo Therapeutics, Inc. - Special Call

Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy

Oct 7, 2025, 6:00 AM EDT - 5 weeks ago

Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy

Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights

Aug 14, 2025, 7:30 AM EDT - 3 months ago

Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights

Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia

Jul 7, 2025, 7:00 AM EDT - 4 months ago

Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia

Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics

Jun 24, 2025, 7:30 AM EDT - 5 months ago

Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics

Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases

May 27, 2025, 7:31 AM EDT - 6 months ago

Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases

Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

May 12, 2025, 7:00 AM EDT - 6 months ago

Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

Lexeo: Alignment Gained With FDA Brings Further LX2006 Program Advancement

May 5, 2025, 2:19 PM EDT - 6 months ago

Lexeo: Alignment Gained With FDA Brings Further LX2006 Program Advancement

Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

May 1, 2025, 9:16 AM EDT - 7 months ago

Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Gene Therapy For Fatal Rare Disease-Associated Heart Condition - Lexeo Therapeutics Candidate Shows Improvements In Trials

Apr 7, 2025, 9:34 AM EDT - 7 months ago

Gene Therapy For Fatal Rare Disease-Associated Heart Condition - Lexeo Therapeutics Candidate Shows Improvements In Trials

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

Apr 7, 2025, 6:00 AM EDT - 7 months ago

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Mar 24, 2025, 7:00 AM EDT - 8 months ago

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 7:30 AM EST - 11 months ago

Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

Dec 19, 2024, 7:00 AM EST - 11 months ago

Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

Nov 13, 2024, 7:30 AM EST - 1 year ago

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference

Oct 30, 2024, 6:14 AM EDT - 1 year ago

Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference

Oct 22, 2024, 7:30 AM EDT - 1 year ago

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

Sep 5, 2024, 7:30 AM EDT - 1 year ago

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further

Jul 16, 2024, 1:17 PM EDT - 1 year ago

Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further

Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet

Jul 15, 2024, 12:05 PM EDT - 1 year ago

Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Jul 15, 2024, 6:00 AM EDT - 1 year ago

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors

Jul 8, 2024, 7:00 AM EDT - 1 year ago

Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors

Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights

May 9, 2024, 7:00 AM EDT - 1 year ago

Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights

Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Apr 22, 2024, 7:30 AM EDT - 1 year ago

Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia Cardiomyopathy

Apr 16, 2024, 7:30 AM EDT - 1 year ago

Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia Cardiomyopathy

Lexeo: Targeted Alzheimer's Disease Treatment Approach Might Pay Off

Apr 9, 2024, 5:26 PM EDT - 1 year ago

Lexeo: Targeted Alzheimer's Disease Treatment Approach Might Pay Off

Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing

Mar 13, 2024, 4:22 PM EDT - 1 year ago

Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Mar 11, 2024, 7:42 AM EDT - 1 year ago

Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing

Mar 11, 2024, 7:30 AM EDT - 1 year ago

Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing

Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments

Feb 5, 2024, 7:00 AM EST - 1 year ago

Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments

Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

Dec 18, 2023, 7:00 AM EST - 2 years ago

Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights

Dec 11, 2023, 7:00 AM EST - 2 years ago

Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights

U.S. IPO Weekly Recap: Biotech Lexeo Stumbles After $100 Million IPO

Nov 4, 2023, 12:21 AM EDT - 2 years ago

U.S. IPO Weekly Recap: Biotech Lexeo Stumbles After $100 Million IPO

ATGL BLMZ HG IPO IPOS KVUE NCI

Lexeo Therapeutics' stock falls 15% in trading debut after its IPO priced below range

Nov 3, 2023, 12:39 PM EDT - 2 years ago

Lexeo Therapeutics' stock falls 15% in trading debut after its IPO priced below range

Lexeo Therapeutics Proposes Terms For $126 Million IPO

Oct 31, 2023, 1:49 PM EDT - 2 years ago

Lexeo Therapeutics Proposes Terms For $126 Million IPO

Lexeo Therapeutics Starts $100 Million U.S. IPO Effort

Oct 2, 2023, 1:49 PM EDT - 2 years ago

Lexeo Therapeutics Starts $100 Million U.S. IPO Effort

RunnerSignals
RunnerSignals Nov. 11 at 9:33 PM
Analysts Spotlight for our pro subscribers $LXEO $ADMA $AMD $ORCL $NVTS are catching analyst attention with strong upside potential https://stocksrunner.com/news/2025-11-11-analysts-spotlight-stocks-with-strong-upside-potential-today
0 · Reply
RunnerSignals
RunnerSignals Nov. 11 at 9:24 PM
Comeback Kings 👑$ACHR $JOBY $TDW $NTLA $LXEO They dipped they flipped they conquered! turned lows into highs classic trader magic
1 · Reply
StockConsultant
StockConsultant Nov. 11 at 3:48 AM
$LXEO Lexeo Therapeutics stock watch, attempting to rally off the 8.31 double support area
1 · Reply
shortkiller7
shortkiller7 Nov. 7 at 3:26 PM
$LXEO is end. Come on $BCAB
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 12:18 AM
Chardan Capital has adjusted their stance on Lexeo Therapeutics ( $LXEO ), setting the rating to Buy with a target price of 17.
1 · Reply
d_risk
d_risk Nov. 5 at 4:20 PM
$LXEO - Lexeo Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors LXEO’s latest 10-Q adds new risks on clinical trial enrollment, orphan/rare disease designations, manufacturing and supply chain issues, reimbursement, privacy/cybersecurity, and expanded regulatory and IP compliance challenges, while removing some prior details on international operations, tax, and cybersecurity breach risks. #Biotechnology #RegulatoryCompliance #ManufacturingRisks #OrphanDiseases #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/LXEO/10-Q/2025-11-05
0 · Reply
JarvisFlow
JarvisFlow Oct. 21 at 11:11 AM
HC Wainwright & Co. updates rating for Lexeo Therapeutics ( $LXEO ) to Buy, target set at 15 → 13.
0 · Reply
DonCorleone77
DonCorleone77 Oct. 17 at 10:56 AM
$LXEO Lexeo Therapeutics 15.625M share Spot Secondary priced at $8.00
0 · Reply
DonCorleone77
DonCorleone77 Oct. 16 at 8:34 PM
$LXEO Lexeo announces common stock and warrants offering, no amount given
0 · Reply
JarvisFlow
JarvisFlow Oct. 15 at 2:26 PM
Guggenheim updates rating for Lexeo Therapeutics ( $LXEO ) to Buy, target set at 30.
0 · Reply
Cinoooo
Cinoooo Oct. 15 at 12:45 PM
$LXEO okay we got a PT of 30 and hit 8.99 PM blast us thru 9 today and let’s hit double digits.
0 · Reply
Cinoooo
Cinoooo Oct. 15 at 1:29 AM
$LXEO one share sold dropped it 2%. Sitting on the sideline watching everything run 20% up got me like
0 · Reply
StreetwiseReports
StreetwiseReports Oct. 10 at 5:05 PM
Therapeutics Company Advances Gene Therapy Breakthrough https://ow.ly/7Vgj50X9Wbc In an updated research note on October 7, H.C. Wainwright & Co. analysts Mitchell Kapoor and Dr. Raghuram Selvaraju note significant risk reduction for Lexeo Therapeutics Inc. ($LXEO:NASDAQ) as formal alignment with the FDA makes its new drug increasingly likely to gain approval.
0 · Reply
StreetwiseReports
StreetwiseReports Oct. 9 at 5:24 PM
Biotech Firm Uncovers Breakthrough Gene Therapy in New York https://ow.ly/uQAf50X9kNq Lexeo Therapeutics Inc. ($LXEO:NASDAQ) advanced its LX2006 program after new FDA feedback supported an accelerated approval path. Read how interim data showed strong cardiac and neurological improvements, prompting bullish analyst upgrades.
0 · Reply
StreetwiseReports
StreetwiseReports Oct. 9 at 5:08 PM
Pharma Announces Faster Approval Pathway for Neurodegenerative Disease https://ow.ly/gYQz50X9kmb Lexeo Therapeutics Inc. ($LXEO:NASDAQ) announces a faster approval pathway for LX2006 in Friedreich's ataxia (FA). Find out why two analysts believe the company is emerging as a leader in developing transformative gene therapies for rare cardiac and neurodegenerative diseases.
0 · Reply
nbkihy8
nbkihy8 Oct. 8 at 3:53 PM
$LXEO I have a feeling they push this green today
0 · Reply
ZenfireTrading
ZenfireTrading Oct. 8 at 1:33 PM
$LXEO Sometimes you only take what you can get! And this is a prime example of it. If you want to see the long/short quant side of the market, visit zenfiretrading.com/join ⚡✨
0 · Reply
boncuk
boncuk Oct. 8 at 12:38 PM
$BJDX $PCSA $TMQ $LXEO thank u for alerts ...
0 · Reply
JarvisFlow
JarvisFlow Oct. 8 at 9:31 AM
HC Wainwright & Co. has updated their rating for Lexeo Therapeutics ( $LXEO ) to Buy with a price target of 15.
0 · Reply
StocktwitsNews
StocktwitsNews Oct. 8 at 4:11 AM
Lexeo Therapeutics Stock Hits 11-Month High On Bullish Analyst Calls For Friedreich’s Ataxia Gene Therapy — Retail Traders Join In $LXEO https://stocktwits.com/news/equity/markets/lexeo-therapeutics-stock-hits-11-month-high-on-bullish-analyst-calls-for-friedreich-s-ataxia-gene-therapy/ch6E3ylR3L3
0 · Reply
Prosperity_Trades
Prosperity_Trades Oct. 7 at 11:55 PM
$TMQ Play of the day with $CISS $GLTO $LXEO
1 · Reply
DayTrade_4Life
DayTrade_4Life Oct. 7 at 9:37 PM
Today's results from the Watchlist and Alerts. See profile for more info and join us. GLTO: $12 to 36.25 (202%) Alert BQ: $22.05 to 46.70 (111%) Weekly Watchlist PRHI: 1.40 to 2.83 (102%); $2 breakout (41%) WL SPRB: $225 to $383 (70%) WL BURU: .30 to .49 (63%) Alert $BJDX: 1.76 to 3.06 (73%); $2 breakout (53%) WL $PCSA: .35 to .44 (25%) WL $TMQ: 5.50 to 7.98 (45%); 7.05 breakout (13%) WL $LXEO: $9 to $10.02 (11%) Alert
1 · Reply